The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

syndevrx.com

SynDevRx has not claimed their Profile.

Want to better differentiate SynDevRx between your competitors? Show buyers how.

BioDelivery Sciences International company logo

Why does SynDevRx win vs. BioDelivery Sciences International?

Show SynDevRx's primary competitive advantage

Show SynDevRx's competitive differentiation

SynDevRx's alternatives and competitors

See how SynDevRx compares to similar products. SynDevRx's top competitors include BioDelivery Sciences International, Amplyx Pharmaceuticals, and Alnylam Pharmaceuticals.

BioDelivery Sciences (NASDAQ: BDSI) is a specialty pharmaceutical company that leverages its novel and proprietary patented drug delivery technologies to develop and co…

SynDevRx vs. BioDelivery Sciences International

View more in-depth data on:

  • Competitors
  • Products
  • Customer References and more
  • Amplyx Pharmaceuticals is a pre-clinical stage small molecule drug development company with a portfolio of internally discovered candidates with improved therapeutic pr…

    SynDevRx vs. Amplyx Pharmaceuticals

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Alnylam Pharmaceuticals (NASDAQ: ALNY) is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company believes that are m…

    SynDevRx vs. Alnylam Pharmaceuticals

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Ra Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the field of complement biology to bring accessible therapies to patients with rare diseases…

    SynDevRx vs. Ra Pharmaceuticals

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3,000 leading acute/intensive care ho…

    SynDevRx vs. The Medicines Company

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Milestone Pharmaceuticals (Nasdaq: MIST) is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug …

    SynDevRx vs. Milestone Pharmaceuticals

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • CytoSolv develops a drug to help heal wounds. The company is developing the drug from the brain cells of pigs.

    SynDevRx vs. CytoSolv

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is …

    SynDevRx vs. Solidus Biosciences

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Xbio Systems has developed the Integrated Drug Development Platform (IDDP), a solution that supports drug and device development by combining process automation, conten…

    SynDevRx vs. Xbio Systems

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Auxeris Therapeutics, Inc. is engaged in osteoporosis drug development

    SynDevRx vs. Auxeris Therapeutics

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • McMillin Pharma is a company seeking to market a high throughput screening method for testing drug libraries in early stage drug development. The technology and screeni…

    SynDevRx vs. McMillin Pharma

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Galantos Pharma is a drug development company focusing on neurodegenerative and psychiatric diseases

    SynDevRx vs. Galantos Pharma

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Cellogico Simulations Allow More Efficient Use Of Resources Through Highlighting Drug Targets With The Greatest Chance Of Success In The Early Stage Of Drug Development…

    SynDevRx vs. Cellogico

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Konova offers anti-obesity drug development

    SynDevRx vs. Konova

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more

You May Also Like

Konova Logo
Konova

Konova offers anti-obesity drug development

C
Cellogico

Cellogico Simulations Allow More Efficient Use Of Resources Through Highlighting Drug Targets With The Greatest Chance Of Success In The Early Stage Of Drug Development.

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

A
Auxeris Therapeutics

Auxeris Therapeutics, Inc. is engaged in osteoporosis drug development

R
Regene Med

RegeneMed, Inc. is accelerating the development of safer, more effective drugs by providing integrated high throughput platforms incorporating engineered human tissue-based assays. RegeneMed possesses patented, proprietary, core technologies enabling the in vitro growth of engineered human tissues, including liver, GI tract, bone marrow and blood-brain barrier. These tissue-based in vitro model systems will accelerate drug development and aims to debottleneck ADME/Tox evaluation, the leading cause of drug failures facing the pharmaceutical industry, per the company.

P
Paloma Pharmaceuticals

Paloma Pharmaceuticals, Inc. is a drug development company focusing on pathologies with a vascular component including cancer, ocular diseases (macular degeneration and diabetic retinopathy), arthritis, fibrotic diseases (pulmonary fibrosis) endometriosis, osteoporosis and skin diseases (psoriasis and atopic dermatitis). Paloma owns the intellectual property relating to a series of , small molecule drugs created through an integrated design platform incorporating , customized and industry standard computational tools that has therapeutic potential for the treatment of the foregoing diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.